Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2021-09-14 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science annonce avoir reçu de nouvelles autorisations portant sur la reprise des inclusions de ses études de phase 3 du masitinib
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that AB Science has received authorizations to resume patient inclusions in its Phase 3 clinical studies for masitinib (ALS and mastocytosis) from regulatory bodies (ANSM, MHRA). This type of announcement, detailing operational updates, regulatory milestones, and general company news, is characteristic of a general regulatory announcement or press release that doesn't fit into the specific financial reporting categories (like 10-K, ER, IR, etc.). Since it is a formal announcement of a significant operational/regulatory event, and it is not a full financial report, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements not covered elsewhere. The document length (7414 chars) is substantial enough that it is not merely a brief notification of a report being available (which would suggest RPA).
2021-09-14 French
AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib
Earnings Release Classification · 1% confidence The document is explicitly titled "**PRESS RELEASE**" and announces specific operational updates regarding regulatory authorizations to resume patient enrollment in clinical trials for a drug (masitinib). This type of announcement, detailing operational progress, regulatory milestones, and often including boilerplate information about the company and the disease areas, is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a press release announcing key operational news rather than a full financial report (10-K, IR) or a transcript (CT), the most fitting category is Earnings Release (ER), which often encompasses significant operational updates released outside of formal quarterly filings. It is not a formal financial report, nor is it a proxy statement or a dividend notice. Given the nature of the announcement (operational update via press release), ER is the best fit among the provided options, although RNS (Regulatory Filings) is a close secondary option if ER is strictly reserved for financial results only. However, press releases announcing significant operational news often fall under ER. FY 2021
2021-09-14 English
AB Science announced today that results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association
Investor Presentation Classification · 1% confidence The document is a press release dated September 13, 2021, announcing the presentation of clinical study results (AB12003 on masitinib) at the American Urological Association (AUA) Annual Meeting, with the abstract published in the *Journal of Urology*. This is not a full Annual Report (10-K), an Interim Report (IR), or a standard Earnings Release (ER). It is an announcement detailing scientific/clinical data presentation, which often falls under Investor Presentations (IP) or general Regulatory Filings (RNS). Given that it details specific study results, design, and scientific conclusions intended for investors and the medical community, 'Investor Presentation' (IP) is a strong fit, as these press releases often accompany or summarize investor presentation materials. However, since it is explicitly a press release announcing results presented elsewhere and published as an abstract, and it doesn't contain the typical structure of a formal investor presentation deck, the most accurate classification for a standalone press release announcing clinical data publication/presentation, especially when it's not a formal earnings report, is often the general 'Regulatory Filings' (RNS) category, or potentially 'IP' if it's considered a substitute for a presentation. Given the detailed scientific nature, 'IP' is plausible, but 'RNS' is the safest catch-all for non-standard announcements. Since it is a detailed announcement of clinical data, which is a key topic for investor relations, I will lean towards Investor Presentation (IP) as it conveys the content type better than the generic RNS, although it is structured as a press release. Revisiting the definitions: IP is 'Detailed presentation for investors focusing on financials, strategy, and market position.' This document focuses heavily on clinical strategy and results. It is a press release *about* a presentation. If the document itself were the presentation slides, IP would be certain. As a press release summarizing scientific findings, it functions similarly to an investor update. Given the options, and the focus on clinical trial results which are crucial for investor assessment, IP is the best fit over the generic RNS.
2021-09-13 English
AB Science annonce que les résultats de l'étude AB12003 du masitinib dans le cancer de la prostate ont été présentés lors du congrès annuel 2021 de l'American Urological Association
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that the results of the AB12003 study on Masitinib in prostate cancer were presented at the AUA annual congress and published in the *Journal of Urology*. It details the study results, design, and provides company information. This format—a formal announcement summarizing key findings and referencing where the full data was presented/published—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical milestones. Since it focuses on presenting key financial/clinical results (even if clinical, it drives investor interest), and is not a full, comprehensive report (like 10-K or IR), the best fit among the provided codes is 'ER' (Earnings Release), as it serves as the initial public announcement of significant performance/study outcomes. It is not a Call Transcript (CT), Investor Presentation (IP), or a Report Publication Announcement (RPA) because it contains substantial content detailing the results, not just announcing the availability of another document. FY 2021
2021-09-13 French
AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that AB Science will present clinical data at an upcoming medical symposium (2021 International Symposium on ALS/MND). It details the abstracts accepted (oral presentation and ePoster) and provides background information on the disease and the drug (masitinib). This type of announcement, focusing on upcoming scientific presentations or key data releases outside of mandatory financial reporting periods (like 10-K or 10-Q), is best classified as a general announcement. Since it is not a formal Earnings Release (ER), a specific regulatory filing (like DIRS or DIV), or a presentation document itself (IP), the most appropriate category is the general Regulatory Filings/Announcements fallback, RNS, as it is a public disclosure of material, non-financial operational/clinical news.
2021-09-02 English
AB Science annonce aujourd’hui que les dernières données cliniques de survie à long terme dans la SLA seront présentées au colloque international 2021 de la SLA et des maladies du motoneurone
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that AB Science will present long-term clinical survival data for ALS at an international symposium (SLA/MND SYMPOSIUM). It details the nature of the presentations (oral presentation and ePoster) and the context (a major medical conference). This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing announcing results (like ER). It is an announcement about participation in a scientific/investor event where data will be presented. This aligns best with an Investor Presentation (IP) or a general announcement. Since it specifically details scientific data presentation at a conference, which is a key activity for investor relations, 'Investor Presentation' (IP) is a strong fit, although it is structured as a press release announcing the presentation of data, rather than the presentation slides themselves. Given the options, and that it is communicating forward-looking scientific/clinical progress to investors, IP is the most appropriate classification over a generic RNS, as it focuses on the content to be presented.
2021-09-02 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.